1. Home
  2. WDS vs RMD Comparison

WDS vs RMD Comparison

Compare WDS & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Woodside Energy Group Limited

WDS

Woodside Energy Group Limited

HOLD

Current Price

$16.12

Market Cap

31.3B

Sector

Energy

ML Signal

HOLD

Logo ResMed Inc.

RMD

ResMed Inc.

HOLD

Current Price

$252.93

Market Cap

36.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WDS
RMD
Founded
1954
1989
Country
Australia
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Medical/Dental Instruments
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
31.3B
36.4B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
WDS
RMD
Price
$16.12
$252.93
Analyst Decision
Hold
Buy
Analyst Count
1
13
Target Price
N/A
$292.27
AVG Volume (30 Days)
584.7K
893.0K
Earning Date
08-18-2025
01-29-2026
Dividend Yield
6.29%
0.95%
EPS Growth
58.72
29.59
EPS
1.54
9.77
Revenue
$13,781,000,000.00
$5,257,400,000.00
Revenue This Year
N/A
$9.85
Revenue Next Year
N/A
$7.32
P/E Ratio
$10.50
$25.82
Revenue Growth
9.53
9.36
52 Week Low
$11.26
$199.92
52 Week High
$17.70
$293.81

Technical Indicators

Market Signals
Indicator
WDS
RMD
Relative Strength Index (RSI) 41.36 48.94
Support Level $16.22 $250.37
Resistance Level $16.98 $259.99
Average True Range (ATR) 0.22 5.54
MACD -0.09 0.57
Stochastic Oscillator 16.91 63.20

Price Performance

Historical Comparison
WDS
RMD

About WDS Woodside Energy Group Limited

Incorporated in 1954 and named after the small Victorian town of Woodside, Woodside's early exploration focus moved from Victoria's Gippsland Basin to Western Australia's Carnarvon Basin. First LNG production from the North West Shelf came in 1984. BHP Billiton and Shell each had 40% shareholdings before BHP sold out in 1994 and Shell sold down to 34%. In 2017 Shell sold its entire shareholding. Woodside is one of the most LNG-leveraged companies globally.

About RMD ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Share on Social Networks: